drugset
drugset / Trial / NCT04674358

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT04674358 ↗

Phase 2/3 Completed 329 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.

Timeline

Start
2020-11-21
Primary completion
2021-09-12
Completion
2021-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.25 % —

Indications

dry eye syndrome